Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 2
2018 2
2019 1
2020 3
2021 2
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
Radiation exposure after 177Lu-DOTATATE and 177Lu-PSMA-617 therapy.
Mair C, Warwitz B, Fink K, Scarpa L, Nilica B, Maffey-Steffan J, Buxbaum S, Virgolini IJ. Mair C, et al. Among authors: maffey steffan j. Ann Nucl Med. 2018 Aug;32(7):499-502. doi: 10.1007/s12149-018-1264-x. Epub 2018 May 23. Ann Nucl Med. 2018. PMID: 29797003
A Randomized, Factorial Phase II Study to Determine the Optimal Dosing Regimen for 68Ga-Satoreotide Trizoxetan as an Imaging Agent in Patients with Gastroenteropancreatic Neuroendocrine Tumors.
Virgolini I, Bahri S, Kjaer A, Grønbæk H, Iversen P, Carlsen EA, Loft M, Knigge U, Maffey-Steffan J, Powell C, Miller CG, Rohban T, McEwan S, Czernin J. Virgolini I, et al. Among authors: maffey steffan j. J Nucl Med. 2022 Mar;63(3):376-383. doi: 10.2967/jnumed.121.261936. Epub 2021 Jul 2. J Nucl Med. 2022. PMID: 34215673 Free PMC article. Clinical Trial.
Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [177Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial).
Ahmadzadehfar H, Rahbar K, Baum RP, Seifert R, Kessel K, Bögemann M, Kulkarni HR, Zhang J, Gerke C, Fimmers R, Kratochwil C, Rathke H, Ilhan H, Maffey-Steffan J, Sathekge M, Kabasakal L, Garcia-Perez FO, Kairemo K, Maharaj M, Paez D, Virgolini I. Ahmadzadehfar H, et al. Among authors: maffey steffan j. Eur J Nucl Med Mol Imaging. 2021 Jan;48(1):113-122. doi: 10.1007/s00259-020-04797-9. Epub 2020 May 8. Eur J Nucl Med Mol Imaging. 2021. PMID: 32383093 Free PMC article.
The 68Ga/177Lu-theragnostic concept in PSMA-targeting of metastatic castration-resistant prostate cancer: impact of post-therapeutic whole-body scintigraphy in the follow-up.
Maffey-Steffan J, Scarpa L, Svirydenka A, Nilica B, Mair C, Buxbaum S, Bektic J, von Guggenberg E, Uprimny C, Horninger W, Virgolini I. Maffey-Steffan J, et al. Eur J Nucl Med Mol Imaging. 2020 Mar;47(3):695-712. doi: 10.1007/s00259-019-04583-2. Epub 2019 Nov 27. Eur J Nucl Med Mol Imaging. 2020. PMID: 31776632 Free PMC article.
Correction to: The 68Ga/177Lu-theragnostic concept in PSMA-targeting of metastatic castration-resistant prostate cancer: impact of post-therapeutic whole-body scintigraphy in the follow-up.
Maffey-Steffan J, Scarpa L, Svirydenka A, Nilica B, Mair C, Buxbaum S, Bektic J, von Guggenberg E, Uprimny C, Horninger W, Virgolini I. Maffey-Steffan J, et al. Eur J Nucl Med Mol Imaging. 2020 Mar;47(3):740. doi: 10.1007/s00259-019-04660-6. Eur J Nucl Med Mol Imaging. 2020. PMID: 31863137 Free PMC article.
Usefulness of combined imaging with 68Ga-DOTATOC PET/CT and spleen scintigraphy in differentiating a neuroendocrine tumour of the pancreatic tail from splenic lesions in a patient with posttraumatic splenosis.
Maffey-Steffan J, Uprimny C, Moncayo R, Kroiss AS, Virgolini IJ. Maffey-Steffan J, et al. Rev Esp Med Nucl Imagen Mol (Engl Ed). 2018 Sep-Oct;37(5):325-327. doi: 10.1016/j.remn.2017.11.005. Epub 2018 May 5. Rev Esp Med Nucl Imagen Mol (Engl Ed). 2018. PMID: 29739708 English, Spanish. No abstract available.
Early PET imaging with [68]Ga-PSMA-11 increases the detection rate of local recurrence in prostate cancer patients with biochemical recurrence.
Uprimny C, Kroiss AS, Fritz J, Decristoforo C, Kendler D, von Guggenberg E, Nilica B, Maffey-Steffan J, di Santo G, Bektic J, Horninger W, Virgolini IJ. Uprimny C, et al. Among authors: maffey steffan j. Eur J Nucl Med Mol Imaging. 2017 Sep;44(10):1647-1655. doi: 10.1007/s00259-017-3743-z. Epub 2017 Jun 6. Eur J Nucl Med Mol Imaging. 2017. PMID: 28589253
68Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour.
Uprimny C, Kroiss AS, Decristoforo C, Fritz J, von Guggenberg E, Kendler D, Scarpa L, di Santo G, Roig LG, Maffey-Steffan J, Horninger W, Virgolini IJ. Uprimny C, et al. Among authors: maffey steffan j. Eur J Nucl Med Mol Imaging. 2017 Jun;44(6):941-949. doi: 10.1007/s00259-017-3631-6. Epub 2017 Jan 31. Eur J Nucl Med Mol Imaging. 2017. PMID: 28138747